Advocacy Clinical Trials Events Information 
Cannabis Law Report
DECEMBER 3, 2021
We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We
Cannabis Law Report
JANUARY 12, 2022
As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
DECEMBER 12, 2022
Comparing psychedelics: dosing and consumption information. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. This stage lasts for 8 to 20 hours.
Cannabis Law Report
JULY 25, 2022
Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. She was Founder and Executive Producer of the award-winning future-shaping events series, Creative Innovation Global.
SMPL
MAY 26, 2020
We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. Mr. Gardner, the writer whose CBD advocacy eventually inspired the 2011 summit at Ms. And with this group, finally, it seemed to be coming together.
The Cannigma
MAY 7, 2021
Now, that’s going to matter significantly when as we advance clinical trials, as we advance product formulation as not just product formulation within pharma but all product formulation and that comes down to the initial process in relation to the supply chain of pretty hardcore standardization. MSO: Absolutely. SM: Yeah, of course.
Cannabis Law Report
NOVEMBER 24, 2021
As sources of medical information, they are relatively under-researched. They restricted information to medical peers and colleagues, keeping ‘specialised’ content from lay audiences (Porter 1992 ). 14) and general information or guidelines for practitioners ( n ?=?6). upcoming seminars).
Expert insights. Personalized for you.
52 
Let's personalize your content